

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/20 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 24.11.2020

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group		N	Result	N _{rel}
(601) A1 expression HER-2/neu					
Slide	(0) not specified	>>>	1	Negative (0)	2,2 %
	(802) Dako HercepTest	>>>	1	Negative (0)	2,2 %
		>	3	Negative (1+)	6,5 %
			1	Weak positive (2+)	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	3	Negative (0)	6,5 %
		>	9	Negative (1+)	20 %
			1	Weak positive (2+)	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	23	Negative (0)	50 %
		>	1	Negative (1+)	2,2 %
	(999) another manufacturer	>>>	3	Negative (0)	6,5 %
Total per sample: n = 46 Success: 96 %					
Total success: 96 %					

(602) A2 expression HER-2/neu

Slide	(0) not specified	>>>	1	Strong positive (3+)	2,2 %
	(802) Dako HercepTest	>>>	5	Strong positive (3+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	13	Strong positive (3+)	28 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	1	Weak positive (2+)	2,2 %
		>>>	23	Strong positive (3+)	50 %
	(999) another manufacturer	>>>	3	Strong positive (3+)	6,5 %
Total per sample: n = 46 Success: 100 %					
Total success: 100 %					

(603) A3 expression HER-2/neu

Slide	(0) not specified	±	1	Weak positive (2+)	2,2 %
	(802) Dako HercepTest	±	2	Negative (0)	4,3 %
		±	2	Negative (1+)	4,3 %
		±	1	Weak positive (2+)	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	±	1	Negative (0)	2,2 %
		±	5	Negative (1+)	11 %
		±	7	Weak positive (2+)	15 %
	(804) Ventana PATHWAY anti-HER-2/neu	±	7	Negative (0)	15 %
		±	13	Negative (1+)	28 %
		±	4	Weak positive (2+)	8,7 %
	(999) another manufacturer	±	1	Negative (1+)	2,2 %
		±	2	Weak positive (2+)	4,3 %
Total per sample: n = 46 Success (only evaluated results): evaluation					

(606) B1 expression HER-2/neu

Slide	(0) not specified	>>>	1	Negative (0)	2,2 %
	(802) Dako HercepTest	>>>	2	Negative (0)	4,3 %
		>	3	Negative (1+)	6,5 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	10	Negative (0)	22 %
		>	3	Negative (1+)	6,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Negative (0)	52 %
	(999) another manufacturer	>>>	2	Negative (0)	4,3 %
		>	1	Negative (1+)	2,2 %
Total per sample: n = 46 Success: 100 %					
Total success: 100 %					

(607) B2 expression HER-2/neu

Slide	(0) not specified	±	1	Weak positive (2+)	2,2 %
	(802) Dako HercepTest	±	1	Negative (1+)	2,2 %
		±	4	Weak positive (2+)	8,7 %
	(803) Dako c-erbB-2 Onkoprotein	±	3	Negative (1+)	6,5 %
		±	10	Weak positive (2+)	22 %
	(804) Ventana PATHWAY anti-HER-2/neu	±	1	Negative (0)	2,2 %
		±	12	Negative (1+)	26 %
		±	11	Weak positive (2+)	24 %
	(999) another manufacturer	±	1	Negative (1+)	2,2 %
		±	2	Weak positive (2+)	4,3 %
Total per sample: n = 46 Success (only evaluated results): evaluation					

(608) B3 expression HER-2/neu

Slide	(0) not specified	>>>	1	Negative (0)	2,2 %
	(802) Dako HercepTest	>>>	5	Negative (0)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	10	Negative (0)	22 %
		>	3	Negative (1+)	6,5 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/20 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 24.11.2020

Test			N	Result	N _{rel}
Sample	Group				
Slide	(804) Ventana PATHWAY anti-HER-2/neu	>>>	20	Negative (0)	43 %
		>	4	Negative (1+)	8,7 %
	(999) another manufacturer	>>>	2	Negative (0)	4,3 %
		>	1	Negative (1+)	2,2 %
Total per sample: n = 46		Success: 100 %			
Total success: 100 %					
(611) C1 expression HER-2/neu					
Slide	(0) not specified	>>>	1	Weak positive (2+)	2,2 %
	(802) Dako HercepTest	>>>	5	Weak positive (2+)	11 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1+)	2,2 %
		>>>	12	Weak positive (2+)	26 %
	(804) Ventana PATHWAY anti-HER-2/neu		1	Negative (0)	2,2 %
		>>>	23	Weak positive (2+)	50 %
	(999) another manufacturer		1	Negative (1+)	2,2 %
		>>>	2	Weak positive (2+)	4,3 %
Total per sample: n = 46		Success: 93 %			
Total success: 93 %					
(612) C2 expression HER-2/neu					
Slide	(0) not specified	±	1	Negative (1+)	2,2 %
	(802) Dako HercepTest	±	1	Negative (1+)	2,2 %
		±	4	Weak positive (2+)	8,7 %
	(803) Dako c-erbB-2 Onkoprotein	±	1	Negative (0)	2,2 %
		±	1	Negative (1+)	2,2 %
		±	11	Weak positive (2+)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	±	2	Negative (0)	4,3 %
		±	20	Negative (1+)	43 %
		±	2	Weak positive (2+)	4,3 %
	(999) another manufacturer	±	2	Negative (1+)	4,3 %
		±	1	Weak positive (2+)	2,2 %
Total per sample: n = 46		Success (only evaluated results): evaluation			
(613) C3 expression HER-2/neu					
Slide	(0) not specified		1	Negative (1+)	2,2 %
	(802) Dako HercepTest	>>>	5	Weak positive (2+)	11 %
	(803) Dako c-erbB-2 Onkoprotein		2	Negative (1+)	4,3 %
		>>>	11	Weak positive (2+)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu		1	Negative (0)	2,2 %
			7	Negative (1+)	15 %
		>>>	16	Weak positive (2+)	35 %
	(999) another manufacturer		1	Negative (0)	2,2 %
		>>>	2	Weak positive (2+)	4,3 %
Total per sample: n = 46		Success: 74 %			
Total success: 74 %					
(616) D1 expression HER-2/neu					
Slide	(0) not specified	>>>	1	Strong positive (3+)	2,2 %
	(802) Dako HercepTest	>>>	5	Strong positive (3+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	13	Strong positive (3+)	28 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Strong positive (3+)	52 %
	(999) another manufacturer	>>>	3	Strong positive (3+)	6,5 %
Total per sample: n = 46		Success: 100 %			
Total success: 100 %					
(617) D2 expression HER-2/neu					
Slide	(0) not specified	>>>	1	Negative (0)	2,2 %
	(802) Dako HercepTest	>>>	2	Negative (0)	4,3 %
		>	2	Negative (1+)	4,3 %
			1	Weak positive (2+)	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	7	Negative (0)	15 %
		>	6	Negative (1+)	13 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Negative (0)	52 %
	(999) another manufacturer	>>>	3	Negative (0)	6,5 %
Total per sample: n = 46		Success: 98 %			
Total success: 98 %					
(618) D3 expression HER-2/neu					
Slide	(0) not specified	>>>	1	Negative (0)	2,2 %
	(802) Dako HercepTest	>>>	4	Negative (0)	8,7 %
		>	1	Negative (1+)	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12	Negative (0)	26 %
		>	1	Negative (1+)	2,2 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/20 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 24.11.2020

Test		N	Result	N _{rel}
Sample	Group			
Slide	(804) Ventana PATHWAY anti-HER-2/neu	>>> 24	Negative (0)	52 %
	(999) another manufacturer	>>> 3	Negative (0)	6,5 %
Total per sample: n = 46		Success: 100 %		
Total success: 100 %				
(621) E1 expression HER-2/neu				
Slide	(0) not specified	± 1	Negative (1+)	2,2 %
	(802) Dako HercepTest	± 5	Weak positive (2+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	± 2	Negative (1+)	4,3 %
		± 11	Weak positive (2+)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	± 1	Negative (0)	2,2 %
		± 9	Negative (1+)	20 %
		± 14	Weak positive (2+)	30 %
	(999) another manufacturer	± 1	Negative (0)	2,2 %
		± 2	Weak positive (2+)	4,3 %
Total per sample: n = 46		Success (only evaluated results): evaluation		
(622) E2 expression HER-2/neu				
Slide	(0) not specified	>>> 1	Negative (0)	2,2 %
	(802) Dako HercepTest	>>> 2	Negative (0)	4,3 %
		> 3	Negative (1+)	6,5 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 10	Negative (0)	22 %
		> 3	Negative (1+)	6,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 23	Negative (0)	50 %
		> 1	Negative (1+)	2,2 %
	(999) another manufacturer	>>> 2	Negative (0)	4,3 %
		> 1	Negative (1+)	2,2 %
Total per sample: n = 46		Success: 100 %		
Total success: 100 %				
(623) E3 expression HER-2/neu				
Slide	(0) not specified	>>> 1	Strong positive (3+)	2,2 %
	(802) Dako HercepTest	>>> 5	Strong positive (3+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 13	Strong positive (3+)	28 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 24	Strong positive (3+)	52 %
	(999) another manufacturer	>>> 3	Strong positive (3+)	6,5 %
Total per sample: n = 46		Success: 100 %		
Total success: 100 %				
(651) A1 sample staining				
Slide	(0) not specified	2	0 points	4,3 %
		> 1	12 points	2,2 %
		>>> 43	15 points	93 %
Total per sample: n = 46		Success: 96 %		
Total success: 96 %				
(652) A2 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		> 10	12 points	22 %
		>>> 1	13 points	2,2 %
		>>> 3	14 points	6,5 %
		>>> 31	15 points	67 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(656) B1 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		>>> 45	15 points	98 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(658) B3 sample staining				
Slide	(0) not specified	2	0 points	4,3 %
		> 1	12 points	2,2 %
		>>> 1	13 points	2,2 %
		>>> 42	15 points	91 %
Total per sample: n = 46		Success: 96 %		
Total success: 96 %				
(661) C1 sample staining				
Slide	(0) not specified	4	0 points	8,7 %
		> 9	9 points	20 %
		> 1	11 points	2,2 %
		> 1	12 points	2,2 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC2/20 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 24.11.2020

Test		N	Result	N _{rel}
Sample	Group			
Slide	(0) not specified	>>> 31	15 points	67 %
Total per sample: n = 46		Success: 91 %		
Total success: 91 %				
(663) C3 sample staining				
Slide	(0) not specified	5	0 points	11 %
		>	15 9 points	33 %
		>	2 11 points	4,3 %
		>>>	24 15 points	52 %
Total per sample: n = 46		Success: 89 %		
Total success: 89 %				
(666) D1 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		>	6 12 points	13 %
		>>>	39 15 points	85 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(667) D2 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		>>>	45 15 points	98 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(668) D3 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		>>>	45 15 points	98 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(672) E2 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		>>>	45 15 points	98 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(673) E3 sample staining				
Slide	(0) not specified	1	0 points	2,2 %
		>	1 12 points	2,2 %
		>>>	44 15 points	96 %
Total per sample: n = 46		Success: 98 %		
Total success: 98 %				
(681) IQC				
Slide	(0) not specified	1	0 points	2,2 %
			7 3 points	15 %
		>	11 6 points	24 %
		>	1 7 points	2,2 %
		>>>	1 8 points	2,2 %
		>>>	25 9 points	54 %
Total per sample: n = 46		Success: 83 %		
Total success: 83 %				